MC4491 

MC4491 is a selective LSD1/PRMT5 inhibitor, with an IC₅₀ of 0.152 μM against the LSD1/CoREST complex and an IC₅₀ of 0.043 μM against the PRMT5/MEP50 complex. MC4491 induces transcriptomic changes and splicing alterations in AML cells. MC4491 is applicable for the research of acute myeloid leukemia^[1].

MC4491 potently and selectively inhibits both LSD1/CoREST (IC₅₀ = 0.152 μM) and PRMT5/MEP50 (IC₅₀ = 0.043 nM) in biochemical assays, with minimal activity against PRMT1 and PRMT7^[1].
MC4491 (50 nM; 3 days) treatment of MV4-11 AML cells recapitulates the transcriptomic and alternative splicing changes induced by combined PRMT5 and LSD1 inhibition, including activation of myeloid differentiation pathways and suppression of cell cycle-related pathways^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

611.78

C₃₅H₄₅N₇O₃

NC1CC1C2=CC=C(C=C2)NC(CCN3CCC(CC3)NC4=CC(C(NC[C@@H](CN5CCC6=CC=CC=C6C5)O)=O)=CC=N4)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Param NJ, et al. A synergistic interaction between PRMT5 and LSD1 inhibitors in AML. Sci Adv. 2026;12(13):eaea4059.  [Content Brief]